A clinic that orders a peptide vial marked research use only or not for human use and then draws it into a syringe for a patient has not avoided drug law. The Food and Drug Administration looks past the label to how the product is actually marketed and used, and its 2026 warning letters to peptide sellers repeat the same finding: a website describing weight loss, tissue repair, or anti-aging effects establishes human intended use regardless of what the vial says. Once intended human use is established, an unapproved peptide becomes an unapproved new drug under the Federal Food, Drug, and Cosmetic Act, and the exposure runs to the clinic that administers it, not only the company that sold it.
Why FDA Does Not Read the Label at Face Value
FDA's test is intended use, not label text. In its August 24, 2026 warning letter to Peak Performance Peptides, the agency wrote that despite statements on the company's product labeling marketing its products for research use only and not for human consumption, evidence from the company's website established that its products, including retatrutide, semaglutide, and tesamorelin, were intended to be drugs for human use. FDA pointed to a specific detail beyond the marketing copy: the company also sold bacteriostatic water, treated as the means to prepare an injectable drug for human administration. A clinic that keeps reconstitution supplies on hand for RUO vials is building the same record against itself.
The Statute Behind the Warning Letters
The theory FDA applies traces to three provisions. 21 U.S.C. 321(p) defines a new drug as one not generally recognized as safe and effective for use under the conditions in its labeling. 21 U.S.C. 355(a) bars introducing a new drug into interstate commerce without an effective FDA approval. 21 U.S.C. 331(d) makes that introduction a prohibited act. None of the three turns on what the label says. FDA's warning letters to Pinnacle Peptides and Peak Performance Peptides both cite this same chain, and both treat marketing claims of health benefits as proof the RUO disclaimer is false on its face.
From Warning Letters to a Criminal Indictment
The civil warning letter is not the ceiling. On April 1, 2026, a federal grand jury in Utah returned an eight-count indictment against a licensed osteopathic physician for allegedly receiving and selling misbranded, non-FDA-approved peptides, including tirzepatide, semaglutide, BPC-157, and TB-500, to more than 200 patients between February 2024 and April 2025. The peptides allegedly arrived in unlabeled vials, ordered through an intermediary from a company believed to be based in China, and the indictment alleges the physician added labels that did not identify the manufacturer, packer, or distributor, which is itself a basis for misbranding separate from the human-use question. The case shows DOJ is willing to charge a prescriber, not only a seller, when a clinic turns an RUO product into a patient treatment.
The research use only label describes how FDA expects a product to be used. It does not describe how the clinic that bought it actually used it, and that gap is what both the warning letters and the Utah indictment are built on.
The Compounding Pathway Clinics Are Bypassing
A clinic that wants a peptide a licensed pharmacy has not yet put on a shelf still has a lawful route: a 503A/503B pharmacy compounding from a substance on FDA's approved bulks list, under cGMP or USP 797/800 sterile compounding standards, with a beyond-use date backed by real stability data. Buying an RUO vial directly from an online seller skips every one of those controls at once. A clinic that would never accept a compounded drug without a pedigree is, with an RUO peptide, accepting one with no pedigree at all. A registered 503B outsourcing facility also carries mandatory adverse event reporting obligations for compounded preparations. The RUO seller it replaces has no comparable federal duty to report what happens to the patients who receive its product.
Why Early Legal Counsel Is Critical
It is critical that clinics and the compounding pharmacists who supply them promptly retain experienced healthcare defense counsel before continuing to source or administer a research use only peptide, and immediately upon receiving an FDA warning letter, subpoena, or other government inquiry about one. Early legal intervention can protect the provider's rights, ensure an accurate reading of a product's actual regulatory status, avoid inadvertent admissions during an inspection, and preserve defenses that are only available before a warning letter becomes a criminal referral. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance's compounding pharmacy defense attorneys track FDA's warning letters and DOJ's enforcement actions against RUO peptide sellers and the clinics that use them, and translate that record into a defensible sourcing and administration posture. Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience. If your clinic or pharmacy sources, compounds, or administers a peptide carrying a research use only label, contact Health Law Alliance's peptide compounding attorneys for a free, confidential consultation.
